## Ian Tannock

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11472174/publications.pdf

Version: 2024-02-01

1051969 889612 2,808 19 10 19 citations h-index g-index papers 20 20 20 4441 times ranked citing authors docs citations all docs

#	Article	IF	CITATIONS
1	The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research. Lancet Oncology, The, 2021, 22, e369-e376.	5.1	25
2	Value-Added Decisions in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 122-131.	1.8	5
3	The paradox of precision medicine. Nature Reviews Clinical Oncology, 2018, 15, 341-342.	12.5	38
4	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488
5	Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians. Canadian Urological Association Journal, 2017, 12, E59-63.	0.3	1
6	Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer, $2016, 16, 392$ .	1.1	39
7	Perceptions of palliative care among patients with advanced cancer and their caregivers. Cmaj, 2016, 188, E217-E227.	0.9	264
8	Longâ€ŧerm impact of androgenâ€deprivation therapy on physical function and quality of life. Cancer, 2015, 121, 2350-2357.	2.0	47
9	Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet, The, 2014, 383, 1721-1730.	6.3	1,361
10	Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience Journal of Clinical Oncology, 2014, 32, 159-159.	0.8	8
11	Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience Journal of Clinical Oncology, 2014, 32, 61-61.	0.8	2
12	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy Journal of Clinical Oncology, 2014, 32, 70-70.	0.8	3
13	Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) Journal of Clinical Oncology, 2013, 31, 13-13.	0.8	15
14	From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2013, 31, 125-125.	0.8	0
15	Cluster-randomized trial of early palliative care for patients with metastatic cancer Journal of Clinical Oncology, 2012, 30, 9003-9003.	0.8	9
16	Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study Journal of Clinical Oncology, 2012, 30, 9021-9021.	0.8	2
17	Bias in reporting of endpoints of efficacy and toxicity in randomized clinical trials (RCTs) for women with breast cancer (BC) Journal of Clinical Oncology, 2012, 30, 6043-6043.	0.8	2
18	Effectiveness of Specialized Palliative Care. JAMA - Journal of the American Medical Association, 2008, 299, 1698.	3.8	410

#	Article	IF	CITATIONS
19	Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experience. Cancer, 1991, 68, 2120-2124.	2.0	88